Competition from weight loss drugs may affect ResMed's market share in treating sleep apnea.

From Nasdaq: 2024-07-02 13:47:48

– ResMed is facing potential competition from weight loss drugs like Zepbound. Studies show these drugs could reduce the severity of sleep apnea, affecting ResMed’s market share. Motley Fool analysts discuss how this might change the landscape for ResMed and other businesses.

– RXO acquires Coyote Logistics from UPS, expanding its presence in the brokered transportation market. Target partners with Shopify for a mutually beneficial collaboration. Lifetime customer relationships are key for companies like Apple and Costco. Motley Fool analysts explore the impact of these developments on the market.

– Investors are excited about RXO’s acquisition of Coyote Logistics, with shares up over 20%. Eli Lilly’s weight loss drug Zepbound has potential for other applications, creating opportunities and challenges across industries. The future of sleep apnea treatment and the impact on ResMed remain uncertain as more research is needed.



Read more at Nasdaq: How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?